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High resolution proteomics approaches have been successfully utilized for the comprehen-
sive characterization of the cell proteome. However, in the case of quantitative proteomics
an open question still remains, which quantification strategy is best suited for identification
of biologically relevant changes, especially in clinical specimens. In this study, a thorough
comparison of a label-free approach (intensity-based) and 8-plex iTRAQ was conducted as
applied to the analysis of tumor tissue samples from non-muscle invasive and muscle-inva-
sive bladder cancer. For the latter, two acquisition strategies were tested including analysis
of unfractionated and fractioned iTRAQ-labeled peptides. To reduce variability, aliquots of
the same protein extract were used as starting material, whereas to obtain representative
results per method further sample processing and MS analysis were conducted according
to routinely applied protocols. Considering only multiple-peptide identifications, LC-MS/MS
analysis resulted in the identification of 910, 1092 and 332 proteins by label-free, fraction-
ated and unfractionated iTRAQ, respectively. The label-free strategy provided higher pro-
tein sequence coverage compared to both iTRAQ experiments. Even though pre-fraction of
the iTRAQ labeled peptides allowed for a higher number of identifications, this was not
accompanied by a respective increase in the number of differentially expressed changes
detected. Validity of the proteomics output related to protein identification and differential
expression was determined by comparison to existing data in the field (Protein Atlas and
published data on the disease). All methods predicted changes which to a large extent
agreed with published data, with label-free providing a higher number of significant changes
than iTRAQ. Conclusively, both label-free and iTRAQ (when combined to peptide
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fractionation) provide high proteome coverage and apparently valid predictions in terms of
differential expression, nevertheless label-free provides higher sequence coverage and ulti-
mately detects a higher number of differentially expressed proteins. The risk for receiving
false associations still exists, particularly when analyzing highly heterogeneous biological
samples, raising the need for the analysis of higher sample numbers and/or application of
adjustment for multiple testing.
Introduction
Application of mass spectrometry-based quantitative approaches has largely contributed to the
emerging role of proteomics [1]. Quantitative analysis has been widely applied in various pro-
teomics fields such as a) clinical proteomics [2, 3], b) subcellular proteomics [4, 5] or c) interac-
tion proteomics [6, 7]. Moreover, high-resolution, comparative proteomic studies have led to
progress in system biology analysis, particularly in the context of elucidation of the mecha-
nisms underlying pathophysiology of various diseases [8].
Currently, two main types of relative quantification strategies for MS-based proteomics
analysis exist: a) label-based and b) label-free (LFQ) MS-based approaches [9]. In the label-
based approach, the quantification relies on the introduction of stable isotopes. Depending on
the methods for isotope incorporation into the peptides/proteins, several labeling protocols
have been developed including a) metabolic labeling (stable isotope labeling of amino acids in
cell culture), b) chemical labeling (isotope-coded affinity tag, isobaric tag for relative and abso-
lute quantification (iTRAQ), tandem mass tag (TMT)), c) enzymatic labeling (oxygen isotope
(18O)) or d) external addition of the labeled synthetic peptides [9]. Label-based methods allow
for the simultaneous analysis of multiple samples in a single MS run (multiplexing), resulting
in reduced analytical variability. This is particularly relevant for the application of TMT and
iTRAQ labeling, since up to eight (for iTRAQ) [10] or ten (for TMT) [11] samples can be ana-
lyzed simultaneously during a single experiment. In these cases, due to the isobaric nature of
labels, labeled peptides appear as a single peak in the full MS scan. However, upon peptide frag-
mentation at the MS/MS level, the isotope-containing reporter ions are released and distin-
guished according to their masses based on the label composition.
On the other hand, the label-free approach does not utilize stable isotopes. In this case, the
quantification is based on spectral counting and intensity-based measurements. In the former
method, quantification occurs at the MS/MS level utilizing the number of fragmentation spec-
tra assigned to peptides that belong to a particular protein. On the contrary, the intensity-
based quantification method is applicable at the MS1 level and the quantification is based on
the estimated area under the curve from the extracted ion chromatogram [9].
Both, iTRAQ and label-free quantification have been widely applied in proteomic research.
Up to date, several studies have been published in order to evaluate their analytical perfor-
mance including precision, accuracy of quantification, protein sequence coverage and quantifi-
cation reproducibility [12–16]. In a few studies, an additional effort was made to evaluate the
biological significance of the findings. These studies included evaluation of a) two Chlamydo-
monas reinharditii strains in the context of biofuel production [16], b)Methylocella silverstris
bacterium cultured under various conditions [13] and c) adenovirus infection of human lung
cells [15]. In the aforementioned studies, functional analysis of differentially expressed proteins
identified in label-free and iTRAQ revealed the de-regulation of proteins associated with the
studied process [13, 15, 16]. However, the contribution of the de-regulated proteins to
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particular biological process varies between both approaches [16], likely as a result of the different
analytical performance of both quantification strategies. Along the same lines, a comprehensive
comparison of the two methods, as applied in the analysis of complex biological samples (such as
tumors) has not been reported yet. Both strategies are advocated and might be used as comple-
mentary approaches [17, 18]. Importantly, performance achieved during the analysis of cell lines
or bacterial strains (as has been reported so far) may not be representative when the biological
variability and/or complexity of samples is high. Based on the above, knowledge on the perfor-
mance of these quantification strategies would provide valuable guidance on which method to
use when dealing with complex and heterogeneous material such as clinical samples.
In this manuscript, we describe a side-by-side comparison of the label-free and label-based
(8-plex iTRAQ) methods, with the latter also preceded by an additional fractionation step. The
central goal was to provide recommendations on which approach to use when investigating pro-
tein differential expression in samples typically used in clinical proteomics. In the presented
study, bladder cancer (BCa) tissue specimens representing two different tumor stages (non-mus-
cle invasive vs. muscle invasive) were evaluated. Specifically, the number of identified proteins,
their sequence coverage, consistency of reported changes and reliability of findings as defined by
agreement with existing transcriptomics data were assessed. To reduce quantification bias, we
attempted to unify the sampling process by utilizing aliquots of the same tissue extracts to obtain
as representative as possible results per method. Sample processing and analysis by mass spec-
trometry were performed according to regularly used/optimized protocols per method.
Materials and Methods
Clinical samples
Bladder cancer tissue specimens were collected from patients undergoing transurethral resec-
tion of bladder cancer in medical centers in Greece (Laikon Hospital, Athens) and Germany
(Department of Urology and Urological Oncology, Hannover Medicine School). The studies
were approved by the respective local ethics committees (for Athens Ε.S 618–2012 and for
Hannover 614–2009) and all individuals gave written informed consent. Samples from tumor
tissue from 8 patients were employed for the analysis including non-muscle invasive (stage
pTa, n = 4) and muscle invasive bladder cancer cases (stage pT2+, n = 4). Tumor stage was
determined according to TNM classification system [19].
Sample preparation
Approximately 20 mg of bladder cancer tissue was homogenized in 150 μL of lysis buffer (4%
SDS, 0.1M DTE, 0.1M Tris-HCl pH 7.6) using blade homogenizer (three cycles of 30 – 40s) fol-
lowed by sonication (15 s per sample). This protein extraction protocol was selected following
preliminary experiments testing the performance of different homogenization means such as
homogenization by using liquid nitrogen, Potter homogenizer or ultrasonication (data not
shown). Undissolved materials were removed by centrifugation at 13000 rpm for 10 min. Pro-
tein concentration was determined by the Bradford assay (BioRad) and protein extracts were
processed using the FASP [20], separately for LFQ and iTRAQ experiments.
Label free analysis. Equal amount of protein (200 μg) per sample prepared as described
above was first subjected to buffer exchange in Amicon Ultra Centrifugal filter devices (0.5 mL,
30 kDa MWCO, Millipore) at 13 000 rpm for 15 min at room temperature. The protein extract
was mixed with 200 μL of urea buffer (8M urea in 0.1M Tris-HCl pH 8.5) and centrifugal con-
centration was performed. The concentrate was then diluted with urea buffer and centrifuga-
tion was repeated. Subsequently, alkylation of proteins was performed by adding 100 μL of
0.1M iodoacetamide in urea buffer followed by 20 min incubation in the dark. Samples were
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centrifuged at 13 000 rpm for 10 min. Additional series of washes were conducted with urea
(twice) and ABC buffer (50 mM NH4HCO3 pH 8, twice). Overnight digestion was performed
by adding 2 μg of trypsin (stock solution of 500 ng/μL) in 40 μL of ABC (trypsin to protein
ratio 1:100). Peptides were eluted by centrifugation followed by washing with 40 μL of 50 mM
NH4HCO3. Afterwards, samples were lyophilized.
8-plex iTRAQ labeling. 100 μg of protein extract was processed by FASP as described
above with the following modifications a) 50 mM trietylamonium bicarbonate (TEAB) was used
instead of ABC buffer, b) 1 μg of trypsin was added in 20 μL of 50 mMTEAB and c) peptides
were eluted with 20 μL of 50 mMTEAB. Tryptic digest peptides were labeled using the 8-plex
iTRAQ Reagent kit (AB Sciex) according to manufacturer instructions. Samples from non-inva-
sive tumor tissue (pTa stage) were labeled using 113–116 tags, whereas for the invasive tumors
(pT2+) 117–119 and 121 tags were used. Subsequently, 8 individual samples were mixed and
lyophilized to dryness. To remove excess of the iTRAQ reagents, peptides were re-suspended in
0.1% formic acid and 80 μg were purified using Pierce C18 Tips, 100μL bed (Thermo Scientific)
according to manufacturer instructions. As an alternative approach, a high pH reverse phase
chromatography on a Dionex P680 HPLC system was applied to purify and pre-fractionate the
remaining peptide mixture (* 700 μg). Labeled peptides were lyophilized and redissolved in
250 μL of high pH buffer (0.05% NH4OH, pH 9–9.5) by sonication in a water bath. The solution
was filtered using syringe driven filter unit (0.22 μMPVDF). After loading of 200 μL onto an
XBridge 4.6 x 150 mm C18 column (BEH Technology) at flow rate of 0.4 mL/min in 0.05%
NH4OH, the sample was eluted with a gradient of solvent A: 0.05% NH4OH in water versus sol-
vent B: 0.05% NH4OH in 100% acetonitrile starting at 5% B for 15 min, then to 35%B at 25 min
then to 80% B at 30 min followed by 5 min rinsing at 80% B. In total, 5 fractions of 1.2 mL were
collected starting from 21 min up to 35 min of the gradient. Prior to the LC-MS/MS analysis, 3 of
these fractions with the lowest peptide content (1, 4 and 5) were pooled.
LC-MS/MS analysis
10 μg of protein digest were loaded onto a Dionex Ultimate 3000 RSLS nano flow system (Dio-
nex, Camberly UK). After loading onto a Dionex 0.1×20 mm 5 μmC18 nano trap column at a
flow rate of 5 μl/min in 0.1% formic acid and 2% acetonitrile, samples were applied onto an
Acclaim PepMap C18 nano column 75 μm×50 cm, 2 μm 100 Å at a flow rate of 0.3 μl/min. The
trap and nano flow column were maintained at 35°C. The samples were eluted with a gradient
of solvent A: 0.1% formic acid versus solvent B: 80% acetonitrile starting at 1% B for 5 min ris-
ing to 5% B at 10 min then to 25% B at 360 min and 65%B at 480 min.
The eluent was ionized using a Proxeon nano spray ESI source operating in positive ion
mode into an Orbitrap Velos FTMS (Thermo Finnigan, Bremen, Germany). Ionization voltage
was 2.6 kV and the capillary temperature was 200°C. The mass spectrometer was operated in
MS/MS mode scanning from 380 to 2000 m/z. The top 20 multiply charged ions were selected
from each scan for MS/MS analysis using CID at 40% collision energy. The resolution in MS1
was 60,000 and 7,500 at m/z 400 for CID in MS2. For the iTRAQ samples, the top 20 multiply
charged ions were selected from each scan for MS/MS analysis using HCD at 45% collision
energy. AGC settings were 1,000,000 for full scan in the FTMS and 200,000 for MSn. Resolu-
tion in MS2 at m/z 115 was 16,300. Dynamic exclusion was enabled with a repeat count of 1,
exclusion duration of 30 seconds.
Data processing
The processing of the individual raw MS data files was conducted using the commercially avail-
able software Proteome Discoverer v. 1.4.0.288 (Thermo Scientific). An event detection node
Label-Free vs. iTRAQ: Analysis of Tissue Samples
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was used at a setting of 2 ppm along with the precursor ion peak detector node. Database
search was carried out against Human Swiss-Prot Database (30/10/2013) [21, 22] containing
only the canonical sequences with 20 277 entries using the Sequest search engine [23] imple-
mented in Proteome Discoverer. The following search parameters were applied: a) precursor
mass tolerance 10 ppm, b) fragment mass tolerance: 0.8 Da and 0.05 Da for label-free and
iTRAQ experiments, respectively, c) fixed modification: carbamidomethylation of cysteine (C)
and additionally for the labeling experiment an iTRAQ modification of N-terminus and lysine
residues were added, d) variable modification: oxidation of methionine (M) and in the case of
iTRAQ, the iTRAQmodification on tyrosine (Y) was added, e) allowing one missed cleavage
site. The false discovery rate evaluation was performed by using the Percolator node [24] (Pro-
teome Discoverer 1.4). To verify labeling efficiency, an additional search was performed by set-
ting the iTRAQ 8-plex labels as variable modifications on N-terminus and Lysine (K). In
parallel, the prevalence of the modifications (including oxidation, chemically induced cysteine
modification, chemical and posttranslational modifications) was evaluated by using Preview™
node (v2.6.46, Protein Metrics Inc.) [25] incorporated in the Proteome Discoverer workflow.
To this end, a search was performed for the selected data files from each experimental
approach incorporating the modifications indicated above. The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Consortium [26] via the PRIDE partner
repository with the dataset identifier PXD002170.
Protein Identification
The same selection criteria were applied for protein identification in both approaches. Identi-
fied peptides were initially filtered requiring mass deviation below 5 ppm between experimen-
tal and theoretical mass, false discovery rate below 1% (assigned in Proteome Discoverer as
high confidence peptides) and peptide rank up to 5. Peptides were excluded if they contained
an unknown amino acid (X) in the sequence or if the protein accession could not be mapped.
In the case of the label-free approach, the list of the non-redundant peptides for the entire
experiment was then generated, based on the individual datasets (due to its multiplexity nature,
merging was not required in the case of iTRAQ). During the merging of the individual datasets
from the label-free experiment, only peptides with an FDR<1% were included. FDR level was
not assessed again after merging of the data. If sequences with identical number of modifica-
tions, although in different position, were reported, only one sequence was retained. For each
spectrum (as defined by the same m/z and retention time), the best candidate sequence was
defined based on the relative number of sequence identifications per sample (e.g. the sequence
with the highest number of identifications was maintained). The confidence in the interpreta-
tion (based on the XCorr) was taken into consideration in cases where the same number of
sequence identifications was reported. Additionally, only peptides consistently reported in
more than 75% of the samples (at least in one group: pTa and/or pT2+) were considered as
credible. Subsequently, peptides were assigned to the protein according to the Occam Razor
principal [27]. All peptides derived from keratins were excluded as probable contaminations,
and were not taken into consideration during the subsequent analysis. Only proteins identified
based on2 peptides were considered for further comparative analysis.
Relative Quantification
Label-free quantification. The peak area-based quantification uses precursor ions to
assess the relative abundance of identified proteins in the label-free data. For each precursor
ion, peak area (i.e. area under the curve) is calculated from the extracted ion chromatogram
during data processing in Proteome Discoverer by using the Precursor Ions Area Detector
Label-Free vs. iTRAQ: Analysis of Tissue Samples
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node. For the sequences for which no peptide area could be integrated by Proteome Discoverer
(version 1.4; this is a well-known, but not yet corrected problem of this software), the absent
values were replaced with the mean area values calculated in that group (pTa or pT2+). When
the peptide was not identified in the particular sample, the missing values were replaced with
zero. Part per million (ppm)-normalization was conducted for the selected peptides according
to the following formula: Normalized peak area = (Peptide peak area/Total peak area)×106.
Protein abundance in each sample was calculated as the sum of all normalized peptide areas
for a given protein. Peptides matching to multiple protein IDs were included only for the quan-
tification of the one protein indicated by the Occam Razor rule [27]. The mean protein abun-
dance per groups was then calculated and the average values were log2 transformed. The log2
ratio was then calculated by the subtraction of the log2 transformed mean value obtained for
case and controls [ log2
case
control
¼ Log2Avg:Cases Log2Avg:Controls ].
Label-based quantification. All quantification steps were performed using the Proteome
Discoverer Software (version 1.4). The 8-plex iTRAQ quantification was performed based on
the reporter ion intensities detected by the Reporter Ions Quantifier Node in Proteome Discov-
erer. The reporter ion intensities were corrected for the isotopic impurities using reporter ion
isotopic distribution (S1 Table). When the individual reporter intensities were 0 (the reporter,
or mass, tags are missing in the quantification spectrum), the minimal reported intensity was
assigned to the respective peptide. To provide an accurate quantification of proteins, only pep-
tide spectrum matches with co-isolation interference below 30% were included in the analysis
[28]. Subsequently, for each distinct peptide the abundance was calculated as the median of
reporter ions from all matching spectra, since median is more resistant to outliers. Spectra
were grouped based on mass and sequence, without taking into consideration the peptide
charge. In the case of modifications, the peptides were considered as distinct when modifica-
tions were different. The reporter ion intensities for each individual peptide were represented
as a ratio of the particular reporter ion to the sum of all reporter (as in the case of Libra imple-
mented in Trans Proteomic Pipeline Software [29]). To account for experimental biases (e.g.
unequal loading), the quantification values for each channel were balanced to be equal to
12.5%, which corresponds to the contribution of 1 out of 8 labels for quantification. This is
based on the assumption that the reporter ions are ionized with the same efficiency and in the
case of equal loading comparable total intensity of reporter ions should be obtained for each
label. For protein quantification, only unique peptides were taken into consideration. For each
label, protein abundance was defined as the average of the peptide quantification values
belonging to the given protein, which is expected to better reflect the overall change at the pro-
tein level (in comparison to using the median values), due to the expected ionization efficiency
differences among different peptides. Subsequently, the average values were calculated for
cases and controls, and these values were log2 transformed. The ratio was calculated by follow-
ing subtraction of the mean value obtained for case and controls, as in the case of label-free
approach. As an alternative quantification strategy (referred as analysis 2), balanced quantifica-
tion values were employed to calculate the peptide ratio. The latter was expressed as a ratio of
quantifications values corresponding to pT2+ vs. pTa samples. Similarly, only unique peptides
were considered for protein quantification. Protein ratio was calculated by the averaging of all
quantifiable peptide ratios belonging to each protein and the ratio values obtained were subse-
quently log2 transformed.
Statistical analysis
Statistical analysis was performed using SPSS Statistical Software (SPSS 17.0, IBM). For each
quantification method, the p-value was calculated for the log2 transformed values by using
Label-Free vs. iTRAQ: Analysis of Tissue Samples
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independent sample t-test. In the case of the alternative quantification approach tested for the
iTRAQ (analysis 2), the p-value was calculated based on the normal distribution of the ratios
by using R programming language. Proteins with a p-value below 0.05 were considered as sta-
tistically significant. Pearson correlation and regression analysis was calculated in MedCalc
Version 12.1.0.0 (Mariakerke, Belgium).
Assessment of reliability of protein identification and differential
expression
Validity of the received protein identification was assessed by comparison to expression data
from urinary bladder and/ or bladder cancer tissue reported in the Human Protein Atlas
(http://www.proteinatlas.org/ [30]), ProteomicsDB (http://www.proteomicsdb.org/ [31]) as
well as transcriptomic resources (Bgee Database [32]). Credibility of the regulation trend (up-/
down-regulated in pT2+ vs. pTa), as obtained from the proteomic analysis, was evaluated
based on comparison with the mRNAmicroarray data (GSE3167 [33]) deposited in the Gene
Expression Omnibus [34] as well as literature [35, 36]. The former transcriptomic data
obtained for the pT2+ and pTa bladder cancer stages were analyzed by the GEO2R [37], a web
tool enabling statistical analysis of the data. The information about analyzed samples as well as
the output from the GEO2R is presented in S2 Table. The expression trend reported in proteo-
mics was considered valid when agreement between the proteomic and microarray data was
observed.
Immunohistochemistry
Immunohistochemical evaluation of Annexin A6 expression (Annexin VI Antibody (N-19),
polyclonal, anti-goat, Sc-1931, Santa Cruz, AB_630873 Antibody Registry ID, dilution 1:200)
was performed on a tissue microarray containing 35 tissue samples (n = 11 non-cancerous
bladder samples, n = 8 pTa tumors, n = 8 pT1 tumors, n = 8 pT2+ tumors). Further visualiza-
tion was performed with diaminobenzidine according to the manufacturer instruction (ultra-
View Universal DAB Detection Kit) and subsequently sections were counterstained with
hematoxylin. Quantification of the staining was performed with ImageJ software after applica-
tion of color deconvolution [38]. Briefly, 5 images were acquired per section and 10 identical
areas among the sections were selected for measurement. The optical density for the back-
ground was subtracted from all measurements.
Results
Three experimental approaches were evaluated (label-free, unfractionated and fractionated
iTRAQ) aiming to select the optimal strategy for determination of protein differential expres-
sion in highly complex samples employed in clinical proteomics (i.e. non-muscle invasive
(pTa) in comparison to muscle-invasive (pT2+) bladder cancer). The workflow for sample
preparation and data analysis is depicted in Fig 1. Aliquots of the same protein extracts were
used in all cases and all samples were processed by FASP. The lysis buffer was selected based
on preliminary experiments which showed its efficiency (in terms of protein recovery and
reproducibility) for bladder tissue (data not shown). In the case of iTRAQ some minor modifi-
cations of the classical FASP protocol were necessary to ensure compatibility with the subse-
quent labeling, as suggested by the manufacturer and described earlier [39–41]. These include
a reduction of the initial amount of protein processed by FASP (from 200 μg used for LFQ to
100 μg for iTRAQ), and substitution of the ammonium bicarbonate buffer with triethylammo-
nium bicarbonate to avoid interference of the former with labeling via interactions with the
iTRAQ reagents.
Label-Free vs. iTRAQ: Analysis of Tissue Samples
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The impact of possible differences introduced by the sample preparation protocols was
assessed based on the prevalence of defined modifications in both experiments. The analysis
was conducted using Preview™ software [25] and the results were subsequently evaluated
according to the percentage and the fraction of modified peptides (ratio of number of peptides
containing modifications vs. peptides that could possibly contain modification). In general, a
comparable percentage of modified peptides between both approaches (LFQ and iTRAQ) was
obtained, as confirmed by regression analysis (S1 Fig). Most reported modifications were iden-
tical (S3 Table) and the frequency of appearance was generally low. For few modifications,
there was a significant difference between the percentage of modified peptides in LFQ and
iTRAQ including a) formation of Pyro-glu N-terminus, b) carbamylation of methionine, c) N-
terminal acetylation of proteins, d) oxidation of methionine/ histidine/ tryptophan and e) car-
bamidomethylation artifacts.
Fig 1. Experimental workflow. The applied workflow for sample preparation and data analysis for LFQ and iTRAQ quantification is graphically depicted.
doi:10.1371/journal.pone.0137048.g001
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Mass spectrometry and data analysis were performed according to optimized protocols for
each approach, as described in Materials and Methods. In this way, we targeted to obtain unbi-
ased and representative results for each approach.
Protein identification and Quantification
To ensure validity of the findings, only consistently detected peptides (in at least 75% of sam-
ples of one group (pTa or pT2+) were considered in the LFQ approach. As indicated in Materi-
als and Methods, peptides representing possible contaminations such as keratins were
completely removed from the datasets and thus, the corresponding proteins were not taken
into consideration in further analysis. Based on this threshold, an average number of 5184±550
peptide and 1113±78 protein identifications, including single peptide hits, were reported per
LC-MS/MS run (Table 1). In total the LFQ approach enabled the identification of 6871 pep-
tides corresponding to 1346 proteins. For unfractionated iTRAQ, a total number of 1859 pep-
tides and 664 proteins were reported; pre-fractionation of the labeled peptides increased the
identification rate for both, peptides (6099) and proteins (2064). However, in the two iTRAQ
experiments approximately 49% of the reported proteins were represented by a single peptide
only. The respective percentage for LFQ was 32%. Upon exclusion of proteins represented by a
single-peptide, a total of 332, 1092 and 910 protein identifications are received in the unfractio-
nated, fractionated iTRAQ and LFQ experiments, respectively. The lists of identified peptides
and proteins per technique (including also single-peptide identifications) are presented in S4
Table.
The obtained data were subsequently compared at both peptide (Fig 2A) and protein levels
(Fig 2B). For this analysis and to increase reliability of findings only multiple peptides ( 2)
identifications were taken into consideration. As represented in the Venn diagram (Fig 2A),
782 peptides were reported in all three approaches, which corresponds to 42% and 13% of the
total number of the peptides detected by the non-fractionated and fractionated iTRAQ respec-
tively and 11% of peptides identified by the label-free approach. When comparing the data at
the protein level, 280 proteins were found to be detected by all acquisition methods (Fig 2B).
This overlap corresponds to 84% of the proteins identified by iTRAQ unfractionated, 26% for
iTRAQ-fractionated and 31% for LFQ. When comparing the proteins exclusively detected per
method, an approximately two fold higher number of uniquely identified proteins (433 IDs)
was obtained for the pre-fractionated iTRAQ sample as compared to the LFQ (234 IDs); a
Table 1. Overview of the number of peptides and the corresponding proteins as being identified in the individual MS-runs.










Mean (SD)_pT2+ 5368 ± 184 1148 ± 18
iTRAQ 10 μg 1859 664
fractionation 6099 2064
doi:10.1371/journal.pone.0137048.t001
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limited number of proteins exclusively identified in the unfractionated samples was also
observed (5 IDs). Of note, in the LFQ approach all identified peptides and proteins have a
quantification value, whereas 76% (1441 out of 1859 peptides) and 81% (4918 out of 6099 pep-
tides) of the peptides detected by the iTRAQ experiments, without and with fractionation,
respectively, could be quantified, as per the iTRAQ restrictions (unique labeled peptides
detected in all clinical samples with a percentage of the co-isolation interference below 30% are
considered as quantifiable in iTRAQ). At the protein level the vast majority of the proteins
without a quantification value were single-peptide identifications. Of the proteins identified
with at least two peptides, the quantification was not possible for 6 out of 332 and 14 out of
1092 proteins in the case of unfractionated and pre-fractionated iTRAQ sample, respectively.
In the case of the label-based approach, two methods were tested to calculate the abundance
at protein level and subsequently assess the protein ratio. Either by calculating the average pep-
tide quantification values (separately for each label) assigned to the protein (analysis 1) or by
employing the averages of the individual peptide ratios (analysis 2) (as described in detailed in
Materials and Methods). To exemplify differences related to the assessment of protein abun-
dance, the two methods were tested for the data obtained from the fractionated iTRAQ sample.
The obtained results are presented in S4 Table. The methods give highly comparable results:
the ratios for de-regulated proteins (as indicated by the primary analysis, analysis 1) as well as
for whole dataset (including proteins identified with2 peptides) were significantly correlated
between both methods, with the Pearson correlation coefficient of 0.99 (p<0.0001, S2 Fig).
Moreover, comparable numbers of significant changes (p<0.05) were reported using both
methods (45 and 48 for analysis 1 and 2, respectively).
Fig 2. Comparison of peptide and protein identifications in iTRAQ and LFQ experiments. Venn diagrams representing the comparison of all identified
peptides, without considering fixed/variable modifications (A), and proteins (B) from LFQ, fractionated/ unfractionated iTRAQ analysis.
doi:10.1371/journal.pone.0137048.g002
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Coverage of protein sequence
The protein sequence coverage was calculated for all the identified proteins per method and for
the overlapping identifications between the three approaches (Fig 3A). Only multiple-peptide
identifications (2 peptides) were considered. For iTRAQ experiments, a similar protein
sequence coverage was reported for the unfractionated (13%) and fractionated (11%) sample.
In the case of the LFQ, a significantly higher sequence coverage (22%, p<0.001 independent
sample t-test) in comparison to both iTRAQ approaches was observed. This difference was
even more pronounced when considering the overlapping identifications among different
methods (32% vs. 13%/ 18% for LFQ and non-/ fractionated iTRAQ, respectively) (Fig 3A).
The above observations are further supported by the evaluation of the average number of pep-
tides per identified protein (Fig 3C) as well as a comparison of the number of proteins identi-
fied based on particular number of peptides (i.e. 1, 2, 3 and 4 peptides/ protein) per
technique (Fig 3B). As shown, comparable numbers of single-peptide identifications were
reported in LFQ (436 IDs) and iTRAQ-unfractionated (332 IDs). Fractionation of the labeled
peptides increased the number of single peptide identifications substantially to 972 IDs. At the
same time, fractionation also resulted in a higher number of multiple-peptides identifications
( 2 peptides) in comparison to the unfractionated iTRAQ (Fig 3B), but still at an overall
lower average number of peptides per protein in comparison to LFQ (Fig 3C).
Evaluation of differential expression
Assessment of the relative protein abundance is based on the comparison of the quantification
results of pTa (control) versus pT2+ (case) groups. Statistical analysis was used as a criterion to
define the altered protein abundance. Thus, proteins with p-value< 0.05 were considered as
being significantly changed in the case vs. control group. Additionally, the expression trend
Fig 3. Evaluation of protein sequence coverage for LFQ and iTRAQ. Average protein sequence coverage was compared for all identified proteins per
technique as well as for the overlapping identifications (A). The total number of identified proteins based on the particular number of peptides (B) and the
average number of peptides per protein are also presented (C).
doi:10.1371/journal.pone.0137048.g003
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(up- or down-regulation in the case group) is represented by the ratio indicating the changes in
the abundance between pT2+ over pTa BCa samples. Based on the statistical analysis (p<0.05),
LFQ enabled identification of a higher number of differentially expressed proteins (77 proteins,
identification based on at least 2 peptides), even in comparison to pre-fractionation of iTRAQ
(45 proteins). The distribution of up- and down-regulated proteins is presented in Table 2.
Three of these proteins were statistically significant in all three methods (Fig 4). On the other
hand, 65 and 32 proteins were found to be statistically significant only in LFQ and fractionated
iTRAQ samples, respectively (Fig 4). Of the former (65 proteins), as presented in Table 3, 49
proteins were identified by the other techniques but a significant difference in the relative
abundance could not be detected. In the case of fractionated iTRAQ, the majority of proteins
reported as uniquely differentially expressed were not identified by other methods.




¼ Log2Avg:Cases Log2Avg:Controls) proteins were classiﬁed as up/
down regulated in pT2+ group (case group).
As indicated above, a very low number of identifications along with a low number of differ-
entially expressed proteins were reported for the unfractionated iTRAQ approach in compari-
son to the other two techniques. The dataset obtained for the fractionated iTRAQ sample was
considered as more favorable for the label-based approach and was included in further
analysis.
In total, significantly altered levels of abundance (at least according to one quantification
strategy i.e. LFQ and fractionated iTRAQ) were observed for 71 proteins (out of the overlap-
ping 644 proteins detected by both methods).
To further evaluate the consistency of the reported changes to these 71 proteins, S5 Table,
the comparison of their regulation (up-/ down-regulated in pT2+) as reported by the different
methods was performed. As shown (S5 Table), good consistency was observed: 66 proteins
exhibit the same trend of expression, while 5 proteins appear to have inconsistent results
(Table 4). Among the proteins exhibiting a consistent regulation, Annexin A6 was found to be
increased using both proteomic approaches, but statistical significance was reached only for
the case of LFQ. This expression trend was further confirmed by immunohistochemistry (Fig
5). For those 5 inconsistent quantification results observed between LFQ and iTRAQ, a com-
parison of the quantification values at the peptide level was conducted (Table 5). All of the pro-
teins were quantified based on a comparable number of peptides. As presented in Table 5, the
majority of the common peptides used for quantification were characterized by the opposite
expression trend in the two methods.
Validity of protein differential expression
We next evaluated whether the proteins identified as differentially expressed were previously
detected in normal and/or malignant urothelium using various proteomics resources i.e.
Human Protein Atlas (HPA) [30], ProteomicsDB [31], and gene expression database [32] (S6
Table). The expression of almost all differentially expressed proteins (39 out of 45 in iTRAQ
Table 2. Comparison of number of differentially expressed proteins identified by LFQ and iTRAQ approaches.
Regulation Trend ( 2 peptides) LFQ iTRAQ iTRAQ + fractionation
# Up-regulated 49 1 21
# Down-regulated 28 5 24
Total 77 6 45
doi:10.1371/journal.pone.0137048.t002
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and 64 out of 77 in LFQ, respectively) have been confirmed in normal and/or tumorous
urothelium in all data repositories.
In an effort to further investigate the validity of the proteomics results, we compared them
to transcriptomics data [33, 35, 36] from comparison of BCa vs. normal tissue [35], high vs.
Fig 4. Comparison of differentially expressed proteins identified in both iTRAQ experiments and LFQ.
Venn diagrams representing differentially expressed proteins found among the identified proteins after
exclusion of single peptide hits.
doi:10.1371/journal.pone.0137048.g004
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low grade bladder cancer [36] and/or invasive (pT2+) vs. non-invasive (pTa) BCa (Gene
Expression Omnibus ID: GSE3167 [33]) (S6 Table).
The summary of the obtained results for datasets derived from the fractionated iTRAQ and
LFQ is presented in Table 6. Of the differentially expressed proteins detected by LFQ 44% (34/
77) were also found to be differentially expressed at the mRNA level (S6 Table). In the case of
significant changes according to fractionated iTRAQ, the expression trend of 15 out of 45 pro-
teins (33%) was in agreement with the microarray data. As aforementioned, a comparison of
the differentially expressed proteins revealed several proteins as being significant only accord-
ing to one approach.
Of proteins that were detected in both approaches, but found as differentially expressed
only based on one approach, 18 out of 45 for LFQ and 3 out of 14 for iTRAQ were also found
to be differentially expressed at the mRNA level (Table 6, Overlapping IDs). In the case of the
identifications solely detected by one technique (20 for LFQ and 19 for iTRAQ), the differential
expression of 13 proteins (LFQ) and 9 proteins (iTRAQ) was supported by the mRNA data
(Table 6, Unique IDs).
Discussion
Since the introduction of the iTRAQ labeling as a quantification strategy for shotgun proteo-
mics [42], several studies have been published aiming at the comparative analysis of label-free
and iTRAQ performance [12–16]. Considering the advantages of multiplexing, MS analytical
time and the total cost of the experiments is relatively lower in the iTRAQ analysis as compared
to the LFQ. Additionally, since all the samples are measured simultaneously in a single MS run,
the inter-run variations of the protein identification and quantification caused by the data-
dependent acquisition do not exist. Reports presented in the past focused on the detailed “tech-
nical” characterizations of the quantification strategies applied in proteomics (including
Table 3. Evaluation of the proteins with the altered abundance found as a unique based on the results obtained for three methods.
LFQ iTRAQ iTRAQ + fractionation
Total number 65 2 32
Proteins identiﬁed in all three approaches 20 1 5
Proteins identiﬁed by two techniques 29 1 9
Exclusively identiﬁed 16 - 18
doi:10.1371/journal.pone.0137048.t003
Table 4. List of proteins with conflicting expression trend.










Actin-related protein 2/3 complex subunit 3 3 -0,25 0.04 a down 2 0.37 0.47 up
Dolichyl-diphosphooligosaccharide—protein
glycosyltransferase subunit 2
7 -0,06 0.58 down 6 1.23 0.02 a up
KH domain-containing, RNA-binding, signal
transduction-associated protein 1
2 -0.25 0.10 down 4 0.63 0.02 a up
General vesicular transport factor p115 4 -0.10 0.57 down 3 0.52 0.04 a up
Heterochromatin protein 1-binding protein 3 3 -0,30 0.04 a down 6 0.72 0.17 up
Proteins that were found to be differentially expressed only according to one quantiﬁcation method. Fold changes and p-values are reported.
a Differentially expressed proteins with p-value <0.05.
doi:10.1371/journal.pone.0137048.t004
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reproducibility, accuracy and precision) [12–16]. To the best of our knowledge a comparison
of LFQ and iTRAQ as applied in the investigation of complex clinical samples has not yet been
presented, especially in the context of the detection of the differentially expressed proteins.
We selected bladder cancer tissue specimens from the non-invasive (pTa) and muscle-inva-
sive disease (pT2+) as a prototypic model for comparing the ability of iTRAQ and LFQ to effi-
ciently detect differentially expressed proteins. In addition to the single LC-MS/MS analysis of
the iTRAQ sample, peptide fractionation prior to LC-MS/MS analysis by using a high pH chro-
matography was also tested. All experiments were conducted using optimized protocols per
technique as reported in the literature, to enable unbiased comparison of the two approaches.
However, in order to minimize potential influence of biological and analytical variability on
the quantification results, we applied, as far as possible, comparable sample processing strate-
gies. Specifically, the same tissue extracts were employed in all cases generated using a protocol
(FASP) for bladder tissue optimized in our laboratory. The FASP approach was selected to
enhance both homogenization and protein solubilization process in bladder tumor specimens.
The analyzed tissue specimens are considered difficult to be homogenized, therefore
Fig 5. Immunohistochemical staining of Annexin A6.Quantification results obtained from non-cancerous tissue and bladder cancer tissues (pTa, pT1
and pT2+) along with the representative images of stained sections are presented. Quantification of the immunoreactivity was conducted by using Image J
software followed by color deconvolution and background subtraction.
doi:10.1371/journal.pone.0137048.g005
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application of buffers containing high concentration of strong detergents (as in the case of
FASP lysis buffer) is advisable. Additionally, application of the same approach for sample prep-
aration and processing is crucial to avoid introducing any analytical bias related to variability
of starting material. Even though the FASP method may not be considered optimal for iTRAQ
analysis, adaptations were made according to existing literature ([39–41] also described in
Materials and Methods). The small difference in the amount of protein initially processed by
FASP (200 μg/ sample in LFQ and 100 μg/ sample in iTRAQ) likely does not affect the obtained
results, since the same amount of protein was finally loaded onto the LC-MS/MS. The lower
Table 5. Comparison of the quantification results at the peptide and protein level for identifications with conflicting expression trends between
fractionated iTRAQ and LFQ.











eASYSLIR -0.24 0.03 -0,30 0.72
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aYLQQLR 0.01 0.61 -0.25 0.37
Actin-related protein 2/3 complex subunit 3 lIGNMALLPIR -0.43 -0.06
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KDDEENYLDLFSHK - 0.39 -0.25 0.63
ILGPQGNTIK - 0.55





SSQTSGTNEQSSAIVSAR - 0.27 -0.10 0.52
SQLNSQSVEITK - 0.25




Similarly to the calculation of the relative abundance at the protein level, the peptide ratio values were calculated based on the log-2 transformed average
vales for cases (pT2+) and controls (pTa).
doi:10.1371/journal.pone.0137048.t005
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starting material in the case of iTRAQ was selected as one vial of the reagent can label between
20 and 100 μg of protein digest. We avoided acetone precipitation, as this can introduce addi-
tional variability and peptide modifications [43]. To assess whether the utilization of different
protocols could introduce unanticipated modifications, we assessed the presence of known
modifications using the Preview™ software [25]. The identity and the prevalence of vast major-
ity of known modifications was similar in the iTRAQ and the LFQ approach (S1 Fig, S3 Table).
This indicates that differences in the sample processing likely did not affect the obtained
results. Following tissue processing, all subsequent steps, including proteins digestion and mass
spectrometry analysis were conducted according to optimized protocols per LFQ and iTRAQ
as described in the literature, in order to obtain representative results per technique.
The pivotal goal of the study was an evaluation of both quantification approaches, label-
based and label-free, particularly focusing on the number and credibility of the identified dif-
ferentially abundant proteins. To address this objective, sequence and proteome coverage as
well as the capability of both techniques to detect the significantly altered proteins and, more
importantly, the credibility of the identified changes were evaluated. This latter assessment was
based on the comparison with existing expression data at the mRNA [32] and protein levels.
The later included data deposited in Human Protein Atlas ([30], http://www.proteinatlas.org/)
and ProteomicsDB ([31], http://www.proteomicsdb.org/) as well as relevant scientific literature
[35, 36]. Since not only protein identification, but also the quantification process might be
uncertain for single-peptide hits, we decided to assess the performance for all three acquisition
methods based on proteins represented by at least 2 peptides identified.
Comparison of proteome coverage
In our study, analysis of bladder tumor samples revealed a more than 2 times higher number of
multiple-peptides based protein identifications in the label-free (910 IDs), than in the iTRAQ
approach (332 IDs). However, this difference appears to be overcome when labeled peptides
are pre-fractionated (1092 IDs). Along the same line, Patel et al. [13] reported a comparable
number of proteins identified by both approaches during proteomics analysis of bacterium
Methylocella silverstris (384 and 425 proteins were identified in iTRAQ and LFQ, respectively).
In this report, the authors applied an additional peptide fractionation step prior to the MS anal-
ysis of iTRAQ samples [13]. In iTRAQ it was shown that, due to an increase in the average ion
Table 6. Assessment of the validity of the differentially expressed proteins identified in proteomics experiments.
Overlapping IDs
Total Similar expression trend with transcriptomics Not conclusive
Signiﬁcant only in LFQ 45 18 27
Signiﬁcant only in iTRAQ 14 3 11
Signiﬁcant in both metods 12 3 9
Unique IDs
Total Similar expression trend with transcriptomics Not conclusive
LFQ 20 13 7
iTRAQ 19 9 10
The validity of the ﬁndings was evaluated by comparing the observed expression trends in this proteomics experiment with several transcriptomic
experiments [35, 36]. Comparison of the detected changes was performed for the differentially expressed proteins reported among overlapping
identiﬁcations between iTRAQ and LFQ as well as for the proteins solely detected in one approach (unique IDs). Proteins exhibiting similar expression
trend in transcriptomics are presented in the “similar expression trend” column. In the cases when the expression trend was not in accordance to mRNA
expression level or the data were not available, the ﬁndings were classiﬁed as “not conclusive”.
doi:10.1371/journal.pone.0137048.t006
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charge state, there is a significant reduction in the number of identifications [44]. Further, the
iTRAQ 8-plex was reported to result in reduced protein annotation rate in comparison to the
iTRAQ 4-plex [10]. During fragmentation, the loss of fragments of the label tag from precursor
ions may occur, which causes some difficulties in the interpretation of the fragmentation spec-
tra by the current search engines leading to the reduced peptide scoring.
We used the same set of tissue extracts for both experiments and sample processing was
comparable (including homogenization and protein digestion), which minimized the biological
and sampling variability on the number of detected proteins by LFQ and iTRAQ. The differ-
ences in fragmentation type of precursor ions, number of MS runs and MS run time are a con-
sequence of utilizing standardized protocols for each strategy. Therefore, the collected data
should reflect the optimized performance of each individual approach per se.
As indicated above, different fragmentation methods for data acquisition were applied:
HCD in iTRAQ and CID in label-free experiments. For iTRAQ, HCD is mandatory for quanti-
fication, since the low masses of the reporter ions prohibit their detection in the ion trap. This
was accompanied with the application of different thresholds for the fragment mass tolerance.
However, this difference has been shown to not have a marked effect on the data [45]. To assess
the possible influence of fragmentation strategy on the observed differences in the number of
identified proteins, one of the selected tissue extracts from the label-free analysis was analyzed
in duplicate under both experimental conditions i.e. CID and HCD fragmentation. This
approach resulted in comparable number of total protein identifications (2270 and 2564 for
CID and HCD, respectively) (S7 Table). Another explanation of the lower number of proteins
identified in iTRAQ is related to the number of MS runs conducted per experiment. Since
data-dependent acquisition is, to some extent, a stochastic process, the number of conducted
MS runs in an experiment has an impact on the total number of identified peptides/ proteins.
In the case of the LC-MS/MS analysis, consistently detected peptides (minimum frequency of
75% in one group) from 8 runs contribute to the total number of identified proteins. On the
other hand, due to the multiplex character of the iTRAQ approach, all samples are analyzed in
a single MS run. Performing duplicate runs of the iTRAQ sample (but in lower quantity than
used for the presented results, e.g. 6 μg) leads to a slight increase in the total number of the
identified proteins from 707/ 663 (for 1st / 2nd run) to 861 (S8 Table). Nonetheless, the num-
ber of identifications is comparable with the results obtained when 10 μg of protein was ana-
lyzed in a single run (664 proteins).
Advantages of iTRAQ are reduced MS run time and the ability to analyze multiple samples
in a single run. Even though multiplexing in the iTRAQ approach may reduce the cost of
experiments (by an 8 fold reduction of the MS run time) as well as decreased the inter-run vari-
ability, the added value of these features appears to be limited. However, after application of
the pre-fractionation step an improved identification rate is achieved, being similar to the
results obtained for LFQ. At the same time an advantage of shorter MS analytical time is main-
tained. In addition, some complementarity of both approaches is demonstrated [17, 18].
Collectively, based on our results, application of the fractionation strategy prior MS run pro-
vides superior results over conventional iTRAQ, and matches the increased number of identifi-
cation in LFQ in part brought about by the multiple MS runs.
Evaluation of quantification strategies
The quantification of the LFQ results was based on the sum of precursor ion areas for all pep-
tides belonging to a protein. In iTRAQ the intensity of reporter ions is utilized. If the ion can-
not be assessed, quantification is not possible [13]. This inability to perform quantification was
experienced in about 6% of all peptides identified. The impaired quantification efficiency in
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iTRAQ might be related to insufficient peptide labeling [13]. However, in our experiments
high labeling efficiency was observed. As an example, in the case of the fractionated iTRAQ
sample, among the group of 1181 unquantifiable peptides (out of 6099), in 75 of these peptides
the quantification value was not reported. High labeling efficiency is also supported by the
results obtained using the Preview software (Protein Metrics Inc) [25]. The efficiency of the
labeling is estimated based on percentage of labeled peptides vs. all possible labeling targets, as
assessed based on the 100 most representative proteins in the dataset [25]. In our case,*98%
of peptides containing K and*100% of peptides N-termini were detected as labeled. Compa-
rable results were also obtained during the additional search in Proteome Discoverer, where
the iTRAQ labels (N-termini, K) were set as variable modification. Over 99% of reported pep-
tides carried the modification on N-terminal residue and/or lysine. In our study, the vast
majority of unquantifiable peptides resulted from the criteria applied for inclusion of peptides
for quantification including percentage of co-isolation interference (939 out of 1181 unquanti-
fiable peptides) and peptide sequence uniqueness (167 out of 1181 peptides). Specifically, co-
isolation (precursor mixing) is a well-known problem in iTRAQ, caused by selection of the pre-
cursor ions in a user-defined m/z window [28, 46, 47]. In this case, the co-isolation of other
precursor ions may lead to contribution of non-related reporter ions to quantification. This
has an impact on the accuracy of the quantification process. Sandberg et al. evaluated the
impact of precursor mixing on the accuracy of the quantification [28]. For this purpose, a lysate
of the breast cancer cell line (MCF7) was spiked with 57 standards and the effect of precursor
mixing was investigated by co-analyzing iTRAQ (8-plex) and TMT (6-plex) labeled peptides.
The bigger impact of the quantification accuracy was observed for the lower abundant proteins,
which are particularly interesting as biomarker candidates. To reduce the effect of the precur-
sor mixing on quantification accuracy, only spectra with the percentage of the co-isolation
interference below 30% were included, yielding a good quantification accuracy [28].
Two different data analysis strategies were employed for the iTRAQ experiment. To keep
similar criteria for identification of differentially expressed proteins between both, iTRAQ and
LFQ, we have calculated the protein abundance based on averaging the quantification values
from associated peptides. However, this approach may affect one of the strengths of the
iTRAQ i.e. quantification at the level of MS/MS spectrum for each individual peptide. Consid-
ering this fact, we compared the conducted data analysis with the classical approach, where the
protein abundance is calculated as an average of the peptide ratios belonging to the protein.
Both methods enabled detection of comparable numbers of differentially expressed proteins,
with the obtained ratios being highly consistent between both approaches, confirming that the
obtained results were not affected by the selection of the quantification workflow. To further
evaluate the quantification results, addition of the internal standard could be of substantial
help and has been proven to be successfully applied by Sjödin et al during the evaluation of
quantification results from various label-based and label-free techniques [14].
Coverage of protein sequence
Our data demonstrate a general increase in protein sequence coverage in LFQ in comparison
to both iTRAQ experiments, in agreement with previously published results [12, 13]. On the
other hand, the limitation of MS-based approaches to identify low abundance proteins during
global-proteomic analysis still exist [48]. Typically, difficulties in the detection of low abun-
dance proteins are related to masking by proteins of higher abundance. During data-dependent
acquisition, not all of the present ions are selected for fragmentation and usually, the ones
excluded are the low-abundance peptides. As a result, the identification of low abundance pro-
teins is often limited to single peptides. The additional pre-fractionation step resulted in an
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increased number of identified proteins with a single peptide. Hence, the application of the
fractionation method may have a clear added value especially for the identification of low
abundance proteins. However, the credibility of these findings has to be carefully assessed by
the other techniques.
Detection of differentially expressed proteins and their biological
reliability
Differentially expressed proteins were defined based on the statistical analysis (p<0.05, indepen-
dent sample t-test) to enable comparison based on the level of confidence. The fold change
threshold was not taken into consideration, since the reported magnitude is not conclusive, par-
ticularly when comparing two quantification approaches which differ in performance. A mean-
ingful comparison of the differential abundance based on the reported ratio appears
questionable, since different thresholds are routinely applicable for each approach. On the other
hand, even if a substantial change is observed, if it is not of statistical significance, then due to the
low confidence should not be reported as a difference. However, when the interpretation of dif-
ferentially expressed proteins in the specific biological context is of highest relevance, the assess-
ment of the reliability of proteomic findings can be supported by volcano plots. The latter
evaluation helps to eliminate apparent significant changes with low fold change, before the spe-
cific FDR is reached; thus the number of false positive changes will decrease in comparison to the
analysis utilizing solely the level of significance as a criterion for defining differential expression.
A higher total number of changes was observed in the LFQ experiment (77 proteins) vs.
both iTRAQ experiments (6 and 45 proteins were reported for the iTRAQ sample, without and
with fractionation, respectively), which corresponds to 8% of total identifications in LFQ and
4% of quantified proteins in the fractionated iTRAQ sample. This trend was also observed pre-
viously by others (e.g. comparison of non-infected vs. infected with adenovirus human lung
epithelial cells A549 [15] or Chlamydomonas reinhardtii sta6 and cw15 strains [16]).
In the data presented here, we observe that the highest fold change range of reported ratios
was reported in label-free (-9.41 up to 9.33) and exceed the range observed in both iTRAQ exper-
iments, being particularly prominent for the un-fractionated (-2.03 up to 1.88) vs. fractionated
sample (-1.72 up to 2.60). This likely reflects underestimations of the ratios in iTRAQ due to iso-
topic impurities, sample complexity or efficiency of chromatography separation and is consistent
with previous studies [16]. Overall, a good agreement in the measured relative abundance, as
defined by the two strategies (e.g. up/ down regulated proteins according to the ratios), was
observed. Preliminary results of immunohistochemical staining (IHC) for Annexin A6 confirm
its increased expression in invasive tumors in line with the proteomics results (Fig 5).
Our analysis showed that among the reported significantly altered proteins (according to at
least one method, LFQ or fractionated iTRAQ) only 5 proteins showed an inconsistency in the
reported ratios. As reported in Tables 4 and 3 out of these 5 proteins were significantly differ-
entially expressed only according to the LFQ analysis, and 2 proteins exhibited a significant
change according to the fractionated iTRAQ. In general, in both approaches confidence in
quantification results is supported by the comparable number of peptides contributing to pro-
tein quantification. On the other hand, since the confidence level of the differential expression
for one of the methods is limited (p>0.05), the validity of the results from this particular
method cannot be established. To evaluate the observed discrepancies, a literature search was
conducted to examine concordance of our findings with published reports. However, the
deregulation of these proteins has not been reported in the context of bladder cancer invasion
(pT2+ vs. pTa). Thus, the reported changes in protein abundance has to be further verified in
independent experiments such as Western Blotting or immunohistochemistry. Preliminary
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results of IHC staining for Annexin A6 confirm its increased expression in invasive tumors in
line with the proteomic quantification results (Fig 5).
To further assess the reliability of the protein identification, the expression of the identified
proteins in urothelium and bladder tumor was checked based on available data from proteo-
mics and transcriptomics resources (S6 Table). The presence of almost all proteins in urothelial
epithelium and/or bladder tumor was confirmed, thus supporting the reliability of the identifi-
cation process. As presented, most of these proteins have been previously identified by other
MS-based or immune-based experiments in the bladder (according to ProteomicsDb [31] or
Human Protein Atlas [30]).
To further assess the credibility of the observed significant changes, a comparison of protein
expression trends with transcriptomic studies [33, 36] for the invasive (pT2+) vs. non-invasive
(pTa) and high versus low grade bladder cancer was performed. With the knowledge that some
of these comparisons may not entirely correspond to changes at the protein level related to inva-
sive versus non-invasive cancers, a higher percentage of confirmed differentially expressed pro-
teins was observed for LFQ (34 out of 77 proteins, 44%) versus fractionated iTRAQ (15 out of 45
proteins, 33%). These data also showed that among the overlapping proteins, but found to be sig-
nificant only according to one method, the 40% and 21% of the changes, as respectively indicated
by LFQ and iTRAQ approach, were confirmed by transcriptomic data. Along the same line, a
higher percentage of the confirmed changes among the proteins solely detected by one approach,
was reported for LFQ (65%) compared to fractionated iTRAQ (47%) (Table 6). Consequently,
based on the higher number of confirmed changes, the LFQ appears to have a better capability to
detect differentially altered proteins in comparison to iTRAQ. However, since many of the
changes could not be supported by the transcriptomic data, to make up for the risk of false associ-
ations received by both techniques, analysis of a higher number of samples and/or more stringent
statistical analysis (e.g. adjustment for multiple testing) may be helpful.
Conclusions
The presented work represents an unbiased comparison of two quantification approaches i.e.
label-free and iTRAQ (unfractionated and fractionated analysis) in order to determine which
technique is better suited for the detection of differential protein expression in clinical samples.
In terms of the number of identified proteins, application of pre-fractionation of iTRAQ
labeled peptides enables superior results over the conventional iTRAQ run; whereas the num-
ber of identified proteins was comparable to the LFQ. Based on the obtained results, the label
free approach appears to be the preferred option, when the detection of differential expression
is a main objective of the study. LFQ provides both a higher number and a higher percentage
of differentially abundant proteins for which the change was also supported by the transcrip-
tomics data. Additionally, the added value of LFQ over the iTRAQ is reflected by the more con-
fident protein identification (higher protein sequence coverage). However, when time on the
instrument or cost is a significant issue, iTRAQ may be the method of choice, when the pre-
fractionation step is applied. Conclusively, label free quantitation may facilitate the characteri-
zation of the molecular mechanisms underlying pathological conditions. However, due to the
possibility to detect false positive changes, an increase in the studied sample sizes, when possi-
ble application of stringent statistical criteria (e.g. adjustment for multiple testing) and further
validation of findings are required.
Supporting Information
S1 Fig. Evaluation of the prevalence of modifications in label-based and label-free experi-
ments using regression analysis (95% CI). Both analysis were performed based on average
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percentage of recognized modifications [number of peptides containing modifications/ num-
ber of peptides that could possibly contain modification  100%]. For iTRAQ, results obtained
from the fractionation experiment are shown. The average percentage of modified peptides
was assessed based on the values obtained separately for each fraction; whereas for the label
free experiment 3 randomly selected samples were evaluated. For the purpose of this analysis,
iTRAQ derived modifications were excluded (Lysine and N-terminus set to a fixed modifica-
tion of 304). The modifications exhibiting significantly different prevalence in iTRAQ and
LFQ were highlighted.
(TIF)
S2 Fig. Evaluation of protein quantification strategies for iTRAQ experiment. Pearson cor-
relation analysis was performed for protein log2 ratios obtained for all quantified proteins (A)
and significantly altered proteins, as indicated by analysis 1 (B). Only proteins identified with
at least 2 peptides were included. In the case of analysis 1, protein abundance relied on the
averages of peptide quantification values for each label and the protein ratio was calculated
based on log2 transformed average values for cases and controls; whereas in the case of analysis
2, the protein ratio was calculated by averaging the ratios for individual peptides and the value
was log2 transformed.
(TIF)
S1 Table. Overview on the reporter ion isotopic distribution for iTRAQ (8-plex).
(DOCX)
S2 Table. Trascriptomics data for pT2+ vs. pTa generated by the GEO2R based on the data
deposited in Gene Expression Omnibus (ID: GSE3167) [33].
(XLSX)
S3 Table. Evaluation of the modification prevalence as calculated by Preview software. The
percentage and the fraction (number of peptides containing modifications vs. number of pep-
tides that could possibly contain modification) are reported for the iTRAQ (non-fractionated/
fractionated) and the LFQ experiments. In the case of the label-based approach supported with
fractionation, the values are presented separately for each fraction); whereas for the label free
experiment three randomly selected samples were evaluated.
(XLSX)
S4 Table. List of identified peptides and proteins in both iTRAQ experiments and LFQ.
Quantification values and expression trends as being obtained by using the label-free and
iTRAQ approach are presented. In addition, in the case of the quantification of the results
obtained after fractionation of iTRAQ sample, the ratios calculated based on the two protocols
i.e. a) averaging of the peptide intensities belonging to protein, which was initially applied as
well as b) alternative approach based on the calculation of protein ratios as an average of the
peptide ratios.
(XLSX)
S5 Table. Comparison of the expression trend for differentially expressed proteins found
among overlapping identifications between LFQ and iTRAQ approach.
(XLSX)
S6 Table. Evaluation of reliability and relevance of identified changes in the iTRAQ and
LFQ approach. The biological reliability of protein identifications was evaluated based on the
data collected in proteomic (Human Protein Atlas [30], ProteomicsDB [31]) and gene expres-
sion (Bgee Database [32]) databases. Additionally, credibility of the detected changes was
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assessed through the comparison of mRNA expression in non-muscle invasive (pTa) vs. mus-
cle invasive BC (pTa) [33], BCa cancer vs. normal tissue [35] and high grade vs. low grade BCa
cancer [36]. (-) This protein-coding gene was not found as differentially expressed in presented
studies. (‡) Proteins characterized by the similar expression trend with the transcriptomic
study.
(XLSX)
S7 Table. Evaluation of the number of proteins identified by using various fragmentation
methods (HCD and CID). Results represent the total number of protein identifications from
duplicate runs for selected sample. The presented lists were exported from Proteome Discov-
erer using following peptide filters: high confidence, ΔM<5ppm and rank 1. Further evalua-
tion, apart exclusion of keratins, was not anticipated for the purpose of this comparison.
(XLSX)
S8 Table. List of proteins identified in duplicate runs of the unfractionated iTRAQ sample.
Common and unique proteins for each run are presented. The presented list of peptides were
exported from Proteome Discoverer using following peptide filters: high confidence,
ΔM<5ppm and rank 1. Further evaluation, apart exclusion of keratins, was not anticipated for
the purpose of this comparison.
(XLSX)
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